Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).

• Small mining outfit Auris Minerals (ASX:AUR) has returned “significant results” from its drilling of gold and base metals at the Morck Well project in WA, specifically at the Jacques East prospect.

Highlights? High-grade gold results: 15m @ 4.11g/t Au from 35m including 4m @ 12.8g/t Au from 38m; 10m @ 1.49g/t Au from 45m; and high-grade, supergene gold mineralisation at Jacques East defined over 70m laterally on section, remaining open along strike to northeast and southwest for up to 400m. 


• Fibre cement gun James Hardie (ASX:JHX) has delivered a strong first quarter ending June 30. In fact, it’s the company’s best ever first quarter results for both Adjusted Net Income and Operating Cash Flow. 

It’s talking:

• Global net sales of US$954.3 million

• Record global adjusted EBITDA of US$279.1 million, with an adjusted EBITDA margin of 29.2%

• Record global adjusted EBIT of US$234.2 million, with an adjusted EBIT margin of 24.5%

• Adjusted net income of US$174.5 million, up 13%

• Adjusted diluted EPS of US$0.39 per share, up 14%

• Operating cash flow increased 64% to US$252.3 million


WT Financial Group (ASX:WTL) – as the name suggests, a financial services group – is up on its full-year indicative results for FY2023. It’s positive, with the headline being revenue and other income up 57% over the prior period to $162.49m (FY22 $103.63). Also, it’s seen a more than doubling of both net profit before tax (NPBT) – up 115% to $5.04m (FY22 $2.35m); and net profit after tax (NPAT) – up 130% to $4.31m (FY22 $1.87m).


• Recce Pharmaceuticals (ASX:RCE) is advancing its testing of RECCE 327 Gel (R327G) through a Therapeutic Goods Administration Special Access Scheme. The drug is designed (but not as yet market approved) for patients suffering antibiotic-resistant Gram-positive and Gram-negative bacterial infections. A positive clinical response has so far been indicated.



Stocks highlighted in yellow have made market-moving announcements (click headings to sort).